Our involvement in the Global Psychedelic Survey 2025 (GPS2025) began through our colleague Dimitris Repantis, who is one of the PsyTrans project partners. Through this connection, Karen Yan and Christina Ni joined as the Taiwan collaborating team, extending the project’s reach across both regions.
Led by the Michigan Psychedelic Center, GPS2025 follows an earlier 2023 survey with 6,000 participants. This time, it’s offered in 18 languages, opening the door to voices from many cultural backgrounds.
The Survey explores how people use psychedelics across different cultures and ask how these patterns might mean for policy and harm reduction strategies. By reaching beyond predominantly English-speaking and Western populations, GPS2025 seeks to capture a more diverse set of perspectives.
A major milestone of this collaboration has been the consortium’s contribution to GPS 2025, which has so far collected responses from 109 countries, with 8,989 respondents reporting their country of residence and around 5,600 completing the full questionnaire. The Taiwan team led the Traditional and Simplified Chinese translations and outreach to Chinese-speaking communities, while the German team contributed German, Greek, Turkish, and Italian translations and supported European community engagement.
Through this effort, perspectives from Taiwan, Germany, and other regions have become part of a broader global dialogue, contributing to a more comprehensive understanding of psychedelic use across different societies.
The consortium is currently co-authoring a GPS 2025 data paper with the international survey team. In parallel, PsyTrans has initiated and leads a separate AI- and machine-learning–oriented multivariate analysis program using the global dataset. This analysis focuses on systems-level associations among use patterns, set and setting, mental health background, motivations, and outcome variables, with particular attention to non-linear relationships and interaction effects.
We look forward to sharing further updates and research outcomes as they become available.